US EditionPublished • loading... • Updated
SPECTRUM PHARMACEUTICALS (NASDAQ: SPPI) CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Investors to Inquire About a Securities Class Action by September 24, 2025
- Berger Montague is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. regarding the company’s misleading statements about its Pinnacle Study between March 17, 2022, and September 22, 2022.
- Investors have until September 24, 2025, to inquire about being lead plaintiff representatives in a class action lawsuit.
- The class action alleges that Spectrum made false or misleading statements regarding its Pinnacle Study related to the drug poziotinib.
- Spectrum shares were delisted following a merger with Assertio Holdings, Inc.
Insights by Ground AI
47 Articles
47 Articles
Rutland Herald+46 Reposted by 46 other sources
SPECTRUM PHARMACEUTICALS (NASDAQ: SPPI) CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Investors to Inquire About a Securities Class Action by September 24, 2025
PHILADELPHIA, Sept. 8, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) ("Spectrum" or the "Company") on behalf of investors who purchased or otherwise acquired common shares of…
Coverage Details
Total News Sources47
Leaning Left2Leaning Right5Center13Last UpdatedBias Distribution65% Center
Bias Distribution
- 65% of the sources are Center
65% Center
C 65%
R 25%
Factuality
To view factuality data please Upgrade to Premium
